Compare Mesoblast Limited (MESO) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs S&P Global Inc — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while S&P Global Inc trades at $406.24 (market cap $118.72B). The key difference: S&P Global Inc is far larger — about 67.8× Mesoblast Limited's market cap, and S&P Global Inc pays a 0.96% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and S&P Global Inc for 123 Days on average.
| MESO | SPGI | |
|---|---|---|
Market Cap | $1.75B | $118.72B |
Volume | 239,027 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $20.96 | $517.92 |
52-Week Low | $13.19 | $370.42 |
Typical Hold Time | 14 Days | 123 Days |
Enterprise Value | $1.83B | $130.21B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust financials with $15.34B revenue and 30.54% net income margin for 2025, while recent earnings show mixed quarterly performance. Analyst consensus remains strongly bullish with an $509.50 price target, supported by 24 buy ratings. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The stock presents a compelling long-term investment opportunity given its strong profitability, market leadership, and analyst support, though technical indicators suggest near-term caution. Key risks include market volatility and execution of growth initiatives, while the 29% upside to consensus target offers significant potential reward for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
